Natco Pharma on Monday said it got final approval for generic Lanthanum Carbonate chewable tablets of 500 mg (base), 750 mg (base), and 1000 mg (base) dosage forms.
Lanthanum Carbonate is a generic equivalent of Shire's Fosrenol Chewable Tablets and reduces the serum phosphate in patients with End Stage Renal Disease (ESRD).
Patients with ESRD typically have high blood phosphate levels that sucks calicium from bone leading to rickets and other bone diseases.
Natco said the product, a first generic, will be launched shortly in the USA market.
Fosrenol chewable tablets had US sales of USD 122.4 million as per the year moving annual total (MAT) ended June.
Natco and Lupin entered into an agreement on September 1, 2008 to jointly commercialise generic equivalents of Fosrenol chewable tablets.
Shares of Natco rose 5.24 percent to close at Rs 739.30 on BSE. Lupin shares gained 2.69 percent to end at 967.60. The bench mark Sensex gained 0.75 to 31,449.03 points.
Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
